Press Releases
Every day, more lives are transformed all over the world – one healthy habit at a time. Read the latest about how Medifast and the OPTAVIA® movement is impacting people’s lives.
Medifast, Inc.
The company's goal of increasing revenues on a lower cost structure will enhance the shareholder value of the business. Medifast, a dynamic business model with increased sales, gross margins and profits, continues to produce high returns while improving cash flow and manufacturing productivity.
Medifast is becoming a leader in disease management with cutting edge branded products, pending patents and technologies. The transformation of Medifast, Inc. into the leading branded, medically supervised, disease management, meal replacement producer on the market, is responsible for doubling revenues for the quarter. Medifast will be conducting groundbreaking clinical trials at Johns Hopkins University Weight Management Center led by Dr. Larry Cheskin, MD with Medifast Plus for Diabetics. During the next two years this study will demonstrate and prove the disease and weight management capabilities of Medifast Plus for Diabetics.
Medifast Plus for Diabetics has received the coveted Seal of Approval from the National Glycemic Institute for its meal replacement shakes, creamy soups, oatmeal, and chili. They are low calorie, low sugar, and low glycemic. Seventeen million diabetics are in need of Medifast Plus for Diabetics.
Chairman MacDonald reiterates, "Investors in Medifast can rest assured that its employees, managers, officers, and directors are focused on increasing revenues, profits, and productivity, which will improve shareholders' equity. Watch the EBITDA and the cash flow of Medifast, Inc. in the next few quarters. Medifast continues to fight nutritional pollution in our society with its `prescription for life' disease and weight management meal replacement products. The health and well being of our patients, along with our shareholders' value, will continue to improve."
This release contains forward-looking statements, which may involve known, and unknown risks, uncertainties and other factors that may cause Medifast's actual results and performance in future periods to be materially different from any future results or performance suggested by these statements. Medifast cautions investors not to place undue reliance on forward-looking statements, which speak only to management's expectation on this date.
SOURCE: Medifast, Inc.
CONTACT: Bradley T. MacDonald, Chairman & Chief Executive Officer of
Medifast, +1-410-581-8042, ext. 231
Web site: http://www.medifast.net/